The Federal Circuit Weighs in On Hatch-Waxman “Skinny” Label Infringement Dispute

The Hatch-Waxman Act allows a generic drugmaker to rely on a branded drugmaker’s Food and Drug Administration-approved New Drug Application if the generic drugmaker can show that the generic drug has the same active ingredient and is bioequivalent to the branded drug……
By: Fish & Richardson
Previous Story

Data Security Update: Humana Customer Information Leaked in Prospect Medical Holdings Data Breach

Next Story

Cell-Cultivated Meats: Nutrition, Safety, and Global Growth